<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <meta name="author" content="Akshay Gulabrao" />
  <title>CAPR Capricor Therapeutics</title>
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    /* The extra [class] is a hack that increases specificity enough to
       override a similar rule in reveal.js */
    ul.task-list[class]{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      font-size: inherit;
      width: 0.8em;
      margin: 0 0.8em 0.2em -1.6em;
      vertical-align: middle;
    }
  </style>
  <link rel="stylesheet" href="style.css" />
</head>
<body>
<header id="title-block-header">
<h1 class="title">CAPR Capricor Therapeutics</h1>
<p class="author">Akshay Gulabrao</p>
<p class="date">2025 October 27</p>
</header>
<p><a href="./index.html">Home</a></p>
<hr />
<p>Capricor Therapeutics (CAPR) has a drug named Deramiocel (CAP-1002)
to treat Duchenne muscular dystrophy. It’s currently in Phase 3 and they
are due to release data in a few weeks.</p>
<p>Martin doesn’t think the drug works.</p>
<p>Duchenne Muscular Dystrophy is a severe X-linked recessive disorder
caused by mutations in the DMD gene, which encodes a structural
cytoskeletal protein in muscle cells named
<strong>dystrophin</strong>.</p>
<p>There are currently a few drugs approved to treat DMD. - Elevidys:
distributes a gene to make dystrophin-like protein throughout muscles -
Emflaza: does not fix dystrophin mutation, but slows the decline in
muscle strength by decreasing IL-1,IL-6, and TNF‑α - Agamree: slows
decline in motor and respiratory function. same result as emflaza, but
different moA - Duvyzat: inhibits HDAC enzymes</p>
<h1 id="elevidys">Elevidys</h1>
<h2 id="primary-endpoint">Primary Endpoint</h2>
<p><a
href="https://jamanetwork.com/journals/jamaneurology/fullarticle/2767086">Elevidys
Clinical Trial Paper</a> <a
href="https://onlinelibrary.wiley.com/doi/epdf/10.1002/ana.26755">Elevidys
Clinical Trial Paper 2</a></p>
<p>The primary outcome measure was Number of Participants with Adverse
Events (AEs). They used 4 people in the study and reported no adverse
events.</p>
<h2 id="secondary-endpoint">Secondary Endpoint</h2>
<p>The change in delandistrogene moxeparvovec dystrophin using western
blot, immunofluorescense, and IF PDPF and the 100-meter timed test.</p>
<p>By western blot,</p>
</body>
</html>
